Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
An automated insulin delivery system consists of three distinct components: a continuous glucose monitor to determine blood sugar levels, a pump to deliver insulin, and an algorithm that uses the data from the CGM and pump to determine needed insulin adjustments. In the United States, the Food and Drug Administration (FDA) allows each component to be approved independently, allowing for more rapid approvals and incremental innovation.
Affair of Half a Lifetime (simplified Chinese: 半生缘; traditional Chinese: 半生緣; pinyin: Bànshēng Yuán) is a 2003 Taiwanese drama-romance TV series based on the 1948 novel of the same name by Chinese author Eileen Chang. It stars Ruby Lin, Patrick Tam, Jiang Qinqin, and Li Liqun. The series had the most simultaneous broadcasts on Chinese cable/satellite TVs in 2004. It was filmed in Shanghai and Taiwan.
Biosimilar insulins, which have a shorter development timeline of about eight years compared to 12 years for novel biologic drugs, provide a more affordable alternative, with development costs ranging from 10% to 20% of those for new biologics. These products could help improve access to treatment and reduce disparities in insulin availability. The global market for biologic medicines, including insulin, grew from $46 billion in 2002 to $390 billion in 2020, accounting for 28% of the global pharmaceutical market. In the United States, biologics represented 43% of drug expenditures, totaling $211 billion in 2019, with biosimilar spending expected to rise from $5.2 billion in 2019 to nearly $27 billion by 2024. In Europe, biologics accounted for 34% of medicine spending, reaching US$78.6 billion in 2021, with the biosimilar market valued at $8.8 billion. The global human insulin market was valued at $22.9 billion in 2020, while the biosimilar insulin market stood at $2.3 billion, projected to grow to $5.6 billion by 2027. The introduction of biosimilar insulins has increased market competition, offering a cost-effective alternative that could lower treatment costs and reduce strain on healthcare systems. Since the approval of the first biosimilar insulin, interest in the products has increased. However, uncertainty regarding their safety and efficacy has slowed their adoption among healthcare professionals.
Sources: en.wikipedia.org
=== Poland: the Catholic Church and Solidarity === Historian Tony Judt, among others, traced communism's collapse back to events in Poland as far back as 16 October 1978, when Karol Wojtyła—Archbishop of Kraków—became the first Polish pope in history. Abandoning his predecessors' cautious Ostpolitik, John Paul II arrived in Warsaw the following June for the first of three pilgrimages to communist Poland, offering the Church not as a passive sanctuary but as an alternative pole of moral and social authority. Communist leaders, faced with the visible enthusiasm the pontiff’s presence elicited, had no viable response, since barring his return would only have deepened his appeal. When Pope John Paul II returned to Warsaw in June 1983 and told an uncomfortable General Wojciech Jaruzelski, on live television, that Poland "must take her proper place among the nations of Europe, between East and West," the Communist leadership could only stand and listen. As Stalin once observed, the Pope has no divisions—yet Wojtyła's visibility and timing emboldened activists who drew up a Charter of Workers' Rights that December, supplying the Polish trade union's eventual base of dissidents and workers with exactly the confidence a state already teetering from its failed food-subsidy strategy could not counter. As a result, Poland's blossoming grassroots Solidarity movement rapidly gained ground with strong popular bases that not only included organized labor, but spread through intellectual networks, and additionally garnered open support from the Catholic Church.
==== Immediate impact on market ==== Tariffs were primarily absorbed by importers by compressing profit margins. Oxford Economics estimated that tariffs contributed about 0.4 percentage points to the 2025 September Consumer Price Index's annual rate of 3.0%, keeping inflation above the Federal Reserve's target. Corporate earnings were significantly affected, with global companies reporting more than $35 billion in tariff-related costs ahead of the third-quarter earnings season. In August 2026, financial markets reacted sharply to heightened geopolitical tensions after President Trump threatened to bomb Oman over the Strait of Hormuz, a move that coincided with the expiration of a 60-day ceasefire arrangement with Iran. On the first day of trading after these events, major U.S. stock indices posted broad declines: the Dow Jones Industrial Average fell 0.51 percent, the S&P 500 dropped 0.52 percent, and the Nasdaq Composite lost 0.32 percent. Within the initial half-hour of trading, roughly $200 billion in market value had been erased. At the same time, the yield on 30-year Treasury bonds climbed to 5.31 percent—its highest point since June 2007—as investors sought safer assets amid rising geopolitical uncertainty and persistent inflation concerns.
=== Latest history === In April 2022, the business announced it would acquire Sierra Oncology Inc. for $1.9 billion ($55 per share). In May 2022, GSK announced it would acquire Affinivax and its phase II 24-valent pneumococcal vaccine candidate for up to $3.3 billion, strengthening its vaccine business. On 16 May 2022, the company changed its name from GlaxoSmithKline to GSK. In April 2023, GSK announced it would acquire Bellus Health Inc. for $2 billion. In February 2024, the company acquired Aiolos Bio for over $1 billion, adding to its existing asthma business through AIO-001, a long-acting monoclonal antibody that targets the thymic stromal lymphopoietin cytokine. In May 2024, GSK sold off its 4.2% shareholding in Haleon for $1.58 billion. In July 2024, GSK moved its headquarters from Brentford to New Oxford Street in central London. As of 2025, capital investments in the company via its American Depository Receipts in New York were outpacing those via the company's primary listing in London. Mounting speculation that GSK would be moving its primary share listing to the New York Stock Exchange, following similar speculation about rival AstraZeneca, has been met with denials from GSK's corporate executives. In September 2025, the company announced Emma Walmsley was stepping down as chief executive at the beginning of 2026. GSK has appointed Luke Miels as her replacement, who has been the company's chief commercial officer since 2017.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.